- Home
- ALLR
as 04-02-2025 4:00pm EST
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 4.0M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -15.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.68 - $174.00 | Next Earning Date: | 05-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Allarity Therapeutics Inc. News
ALLR Breaking Stock News: Dive into ALLR Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
GlobeNewswire
9 days ago
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares
GlobeNewswire
16 days ago
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology
MT Newswires
20 days ago
Allarity Therapeutics Reaches Final Settlement With SEC Over Past Disclosures
GlobeNewswire
20 days ago
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission
GlobeNewswire
a month ago
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
GlobeNewswire
a month ago
Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program
GlobeNewswire
a month ago
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit
Compare ALLR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALLR Allarity Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.